Ginkgo Bioworks, a platform for cell programming and biosecurity, completed the acquisition of the AAV capsid discovery and engineering platform assets of StrideBio, a gene therapy company. Financial terms were not disclosed. "Combining Ginkgo's engineering and discovery capabilities in enzymes, regulatory elements, and capsids enables a holistic approach to designing an AAV gene therapy, so that we can support our partners across the entire process of designing the viral vector. We are thrilled to integrate the STRIVE platform and know-how into our foundry to augment our capabilities in capsid engineering, and we look forward to continuing to expand our existing end-to-end capabilities in AAV discovery and manufacturing," Narendra Maheshri, Ginkgo Head of Mammalian Engineering.